DRRX רווח עתידי DURECT

DURECT (DRRX) - לוגו תאגידי

DURECT Corporation relies on external contractors for drug manufacturing to minimize shortage risks. The business is not subject to the influence of economic cycles or seasonality. The forward earnings metric demonstrates fundamental potential, with the indicator level standing at . Further development is based on the successful completion of clinical trials and obtaining official approvals for the therapy of acute liver pathologies.

DURECT Corp (DRRX): רווח צפוי מ-04.07.2022 עד 17.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור DURECT Corp (DRRX)

- מחיר מניה וקונצנזוס הערכת שווי:
ניתוח פונדמנטלי של החברה:DRRX, DURECT Corp
פריט של המותג DURECT

Asset reliability is determined by a business's ability to generate future cash flows. This indicator aggregates market expectations for net income by extrapolating current growth rates into future periods. For DURECT Corporation (DRRX), the calculation is complicated by a lack of sales and high expenditures on epigenetic research. Negative operating leverage makes the analytical earnings forecast sensitive to the timing of clinical phases. The trend in the analytical earnings forecast helps assess the risk of overpaying for future success.